Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Robier, C; Amouzadeh-Ghadikolai, O; Bregant, C; Diez, J; Melinz, K; Quehenberger, F; Quasthoff, S.
The frequency of occurrence of atypical lymphocytes in peripheral blood smears of natalizumab-treated patients with multiple sclerosis.
Int J Lab Hematol. 2017; 39(5):469-474
Web of Science PubMed FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Quasthoff Stefan
Quehenberger Franz
Robier Christoph
Altmetrics:

Dimensions Citations:

Plum Analytics:
Abstract:
Aside from the extensive published data on immunophenotypic lymphocyte subsets in natalizumab-treated patients with multiple sclerosis (MS), an impact of natalizumab on lymphocyte morphology has rarely been studied. As patients treated with immunomodulating or immunosuppressive drugs are at risk for infectious disorders such as viral infections, knowledge of drug-derived changes in lymphocyte morphology may be beneficial in the diagnostic work-up in such clinical situations. This study aimed to determine the frequency of occurrence of atypical lymphocytes and defined subtypes of variant lymphocytes in natalizumab-treated patients with MS. We compared eight defined morphological lymphocyte subtypes in peripheral blood smears between 14 natalizumab-treated, 13 interferon-treated and 10 untreated subjects with relapse-remitting MS. Atypical lymphocytes were significantly enhanced in natalizumab-treated patients compared to the interferon and control group (P<.0001). Binucleated lymphocytes were restricted to the natalizumab group (P=.0058, P=.018), and plasmacytoid lymphocytes were more frequently found in the natalizumab group (P<.0001). Our data indicate that natalizumab enhances the fraction of atypical lymphocytes, and thereby especially the binucleated and plasmacytoid lymphocytes. Knowledge of these natalizumab-associated changes in lymphocyte morphology may be relevant in clinical routine, to avoid unnecessary diagnostic procedures or even a discontinuation of natalizumab treatment. © 2017 John Wiley & Sons Ltd.
Find related publications in this database (using NLM MeSH Indexing)
Adult -
Biopsy -
Case-Control Studies -
Female -
Humans -
Immunologic Factors - therapeutic use
Interferons - therapeutic use
Lymphocyte Count -
Lymphocyte Subsets - metabolism
Lymphocyte Subsets - pathology
Lymphocytes - metabolism
Lymphocytes - pathology
Male -
Middle Aged -
Multiple Sclerosis - blood
Multiple Sclerosis - drug therapy
Multiple Sclerosis - pathology
Natalizumab - therapeutic use
Young Adult -

Find related publications in this database (Keywords)
atypical lymphocytes
lymphocyte morphology
lymphocytes
multiple sclerosis
natalizumab
© Meduni Graz Impressum